Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CALM1 | P0DP23 | 6/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23266717 | 0.94 | PTGS2 (0.58) | TNKS2PTGS2AKR1B1CYP19A1ALDH1A1 | |
| SCHEMBL5275704 | 0.92 | PTGS2 (0.56) | TNKS2PTGS2AKR1B1CYP19A1ALDH1A1 | |
| SCHEMBL1050377 | 0.92 | PTGS2 (0.56) | TNKS2PTGS2AKR1B1CYP19A1ALDH1A1 | |
| SCHEMBL22598538 | 0.87 | CYP19A1 (0.51) | TNKS2PTGS2AKR1B1CYP19A1ALDH1A1 | |
| SCHEMBL919408 | 0.86 | AKR1B1 (0.55) | TNKS2PTGS2AKR1B1CYP19A1ALDH1A1 | |
| SCHEMBL6568817 | 0.84 | PTGS2 (0.49) | TNKS2PTGS2AKR1B1CYP19A1CALM1 | |
| SCHEMBL920546 | 0.83 | AKR1B1 (0.52) | PTGS2AKR1B1CYP19A1ALDH1A1CALM1 | |
| SCHEMBL10296730 | 0.81 | PTGS2 (0.50) | TNKS2PTGS2AKR1B1CYP19A1CALM1 | |
| SCHEMBL9491787 | 0.81 | CYP19A1 (0.68) | PTGS2AKR1B1CYP19A1ALDH1A1CALM1 | |
| SCHEMBL81474 | 0.80 | CHRM2 (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115385782-A | Mechanochemical synthesis method of benzoyl compound | 兰州大学 | 2022-11-25 | — | — | CN | claimed |
| CN-115385782-A | Mechanochemical synthesis method of benzoyl compound | 兰州大学 | 2022-11-25 | — | — | CN | disclosed |
| WO-2022133544-A1 | CBD CANNABINOIDS AND CBD CANNABINOID ANALOGUES | Botanix Pharmaceuticals Limited (AU) | 2022-06-30 | — | — | WO | disclosed |
| CN-110720456-B | Application of 3, 5-dimethoxytoluene | 西南林业大学 | 2021-11-16 | — | — | CN | disclosed |
| US-9321045-B2 | Catalyst and process for synthesising the same | THE UNIVERSITY OF WARWICK (GB) | 2016-04-26 | — | — | US | disclosed |
| US-9321045-B2 | Catalyst and process for synthesising the same | THE UNIVERSITY OF WARWICK (GB) | 2016-04-26 | — | — | US | disclosed |
| US-20150290634-A1 | Catalyst and Process for Synthesising the Same | THE UNIVERSITY OF WARWICK (GB) | 2015-10-15 | — | — | US | disclosed |
| US-20150290634-A1 | Catalyst and Process for Synthesising the Same | THE UNIVERSITY OF WARWICK (GB) | 2015-10-15 | — | — | US | disclosed |
| EP-2914609-A1 | CATALYST AND PROCESS FOR SYNTHESISING THE SAME | THE UNIVERSITY OF WARWICK (GB) | 2015-09-09 | — | — | EP | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| WO-2008079382-A1 | SPHINGOSINE-1 -PHOSPHATE RECEPTOR AGONIST AND ANTAGONIST COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079382-A1 | SPHINGOSINE-1 -PHOSPHATE RECEPTOR AGONIST AND ANTAGONIST COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
| CN-101081853-A | 4- (hydroxymethyl) -2, 6-dimethoxyphenylboronic acid compound | EISAI CO LTD (JP) | 2007-12-05 | — | — | CN | disclosed |
| CN-101081850-A | 7-phenylpyrazolopyridine compounds | EISAI CO LTD (JP) | 2007-12-05 | — | — | CN | disclosed |
| CN-100338063-C | 7-phenylpyrazolopyridine compounds | EISAI CO LTD (JP) | 2007-09-19 | — | — | CN | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| WO-2006013399-A1 | PHARMACEUTICAL INTERMEDIATES AND A PROCESS FOR THE PREPARATION THEREOF | EGIS Gyógyszergyár Rt. (HU) | 2006-02-09 | — | — | WO | disclosed |
| CN-1705665-A | 7-phenylpyrazolopyridine compounds | EISAI CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
| WO-1998008837-A1 | PHENYLBUTANOL DERIVATIVES, METHODS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | FARMACON, INC. (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290634-A1 | Catalyst and Process for Synthesising the Same | CBR3, SPR, RNF5 | TNKS2 161/4885PTGS2 1318/4885AKR1B1 604/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | TNKS2 2475/4885PTGS2 3624/4885AKR1B1 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.